Tirzepatide (Mounjaro & Zepbound ) Tirzepatide is different because it activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptorsa dual approach that may enhance its effects
Some researchers start even lower with microdosing approaches , where the 0.3 mL syringe is essential
Tirzepatide is a first-in-class T2D medication that activates both the GIP and GLP-1 receptors to help patients better manage blood sugar, while triggering weight loss and improving lipid markers
Patients allergic to tirzepatide, with a history of medullary thyroid cancer, MEN 2 syndrome, pregnant and breastfeeding females, and children should not use tirzepatide
Why it's included Often incorporated to support energy levels and help maintain adequate levels, particularly for patients who may be consuming fewer nutrients
Development timeline for Zepbound Further information Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances
.png)
